BioCardia to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21, 2025
BioCardia (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases, announced its CEO Peter Altman's participation in a fireside chat at the A.G.P. Virtual Healthcare Company Showcase on May 21, 2025. The presentation, scheduled for 3:40 p.m. EDT, will focus on recent business developments and the company's therapeutic pipeline, particularly highlighting their lead product CardiAMP, an autologous cell therapy for treating ischemic heart failure. The session will be moderated by Jim Molloy, AGP's Managing Director of Equity Research Biotechnology & Specialty Pharmaceuticals.
BioCardia (NASDAQ:BCDA), sviluppatore di terapie cellulari e derivate per malattie cardiovascolari e polmonari, ha annunciato la partecipazione del suo CEO Peter Altman a una conversazione informale durante il A.G.P. Virtual Healthcare Company Showcase il 21 maggio 2025. La presentazione, prevista per le 15:40 EDT, si concentrerà sugli ultimi sviluppi aziendali e sul portafoglio terapeutico dell'azienda, con particolare attenzione al loro prodotto principale CardiAMP, una terapia cellulare autologa per il trattamento dell'insufficienza cardiaca ischemica. La sessione sarà moderata da Jim Molloy, Direttore Generale della Ricerca Azionaria in Biotecnologie e Farmaceutica Specializzata di AGP.
BioCardia (NASDAQ:BCDA), desarrollador de terapias celulares y derivadas para enfermedades cardiovasculares y pulmonares, anunció la participación de su CEO Peter Altman en una charla informal durante el A.G.P. Virtual Healthcare Company Showcase el 21 de mayo de 2025. La presentación, programada para las 3:40 p.m. EDT, se centrará en los recientes avances comerciales y en la cartera terapéutica de la compañía, destacando especialmente su producto principal CardiAMP, una terapia celular autóloga para el tratamiento de la insuficiencia cardíaca isquémica. La sesión será moderada por Jim Molloy, Director General de Investigación de Renta Variable en Biotecnología y Farmacéutica Especializada de AGP.
BioCardia (NASDAQ:BCDA)는 심혈관 및 폐 질환을 위한 세포 및 세포 유래 치료제를 개발하는 회사로, CEO Peter Altman이 2025년 5월 21일 A.G.P. 가상 헬스케어 회사 쇼케이스에서 진행되는 파이어사이드 채팅에 참여한다고 발표했습니다. 이 발표는 동부 표준시 기준 오후 3시 40분에 예정되어 있으며, 최근 사업 개발과 회사의 치료제 파이프라인에 중점을 두고 특히 허혈성 심부전을 치료하기 위한 자가 세포 치료제인 CardiAMP를 강조할 예정입니다. 세션은 AGP의 바이오테크 및 전문 제약 주식 연구 담당 상무인 Jim Molloy가 진행합니다.
BioCardia (NASDAQ:BCDA), développeur de thérapies cellulaires et dérivées pour les maladies cardiovasculaires et pulmonaires, a annoncé la participation de son PDG Peter Altman à une discussion informelle lors du A.G.P. Virtual Healthcare Company Showcase le 21 mai 2025. La présentation, prévue à 15h40 EDT, portera sur les récents développements commerciaux et le pipeline thérapeutique de l'entreprise, mettant particulièrement en avant leur produit phare CardiAMP, une thérapie cellulaire autologue pour le traitement de l'insuffisance cardiaque ischémique. La session sera modérée par Jim Molloy, directeur général de la recherche actions en biotechnologie et produits pharmaceutiques spécialisés chez AGP.
BioCardia (NASDAQ:BCDA), ein Entwickler von zellbasierten und zellabgeleiteten Therapeutika für Herz-Kreislauf- und Lungenerkrankungen, gab die Teilnahme seines CEO Peter Altman an einem Fireside-Chat beim A.G.P. Virtual Healthcare Company Showcase am 21. Mai 2025 bekannt. Die Präsentation, die für 15:40 Uhr EDT geplant ist, wird sich auf aktuelle geschäftliche Entwicklungen und die therapeutische Pipeline des Unternehmens konzentrieren, wobei besonders das führende Produkt CardiAMP, eine autologe Zelltherapie zur Behandlung von ischämischer Herzinsuffizienz, hervorgehoben wird. Die Sitzung wird von Jim Molloy, AGP's Managing Director für Equity Research Biotechnologie & Spezialpharmazeutika, moderiert.
- None.
- None.
SUNNYVALE, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that BioCardia’s CEO, Peter Altman, Ph.D., will participate in a fireside chat at the Alliance Global Partners Virtual Healthcare Company Showcase hosted by Jim Molloy, Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals at A.G.P., on May 21, 2025.
Dr. Altman will share recent business developments on the Company’s therapeutic development pipeline with a focus on its lead CardiAMP autologous cell therapy for the treatment of ischemic heart failure.
Fireside Chat Details:
Date: Wednesday, May 21, 2025
Time: 03:40 p.m. EDT
Speaker: Peter Altman Ph.D., CEO
Moderator: Jim Molloy, AGP Managing Director, Equity Research Biotechnology & Specialty Pharmaceuticals
Webcast: https://us02web.zoom.us/webinar/register/WN_jB1HgKLvQFmUfC6VBT11mw
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms. For more information visit www.biocardia.com.
MEDIA CONTACT: Miranda Peto, Investor Relations mpeto@biocardia.com (650) 226-0120 INVESTOR CONTACT: David McClung, Chief Financial Officer investors@biocardia.com (650) 226-0120
FAQ
What will BioCardia (BCDA) discuss at the A.G.P. Healthcare Showcase on May 21, 2025?
Who is presenting at BioCardia's (BCDA) fireside chat on May 21, 2025?
What is BioCardia's (BCDA) main product in development?
What time is BioCardia's (BCDA) presentation at the A.G.P. Healthcare Showcase?
